Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

Keros Therapeutics Price Quote

$50.89
+2.32 (+4.78%)
(Updated: July 23, 2024 at 6:50 PM ET)

Keros Therapeutics Key Stats

Buy
56
Keros Therapeutics (KROS) is a Buy

Day range:
$47.25 - $49.11
52-week range:
$27.02 - $73.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
3.86%

Volume:
322.1K
Avg. volume:
420.3K
1-year change:
12.9%
Market cap:
$1.8B
Revenue:
$151K
EPS:
$-5.15

How Much Does Keros Therapeutics Make?

Data Unavailable

Is Keros Therapeutics Growing As A Company?

Data Unavailable

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$134.8M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $228.1M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.3M

Keros Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KROS return on invested capital is -45.46%
  • What Is Keros Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -41.68%
  • What Is KROS Return On Equity?
    ROE is a measure of profitability and is -45.46%

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • BridgeBio Pharma Inc (BBIO)
    • Biomarin Pharmaceutical Inc (BMRN)
    • Krystal Biotech Inc (KRYS)
    • Sarepta Therapeutics Inc (SRPT)

Keros Therapeutics Dividend Yield

Data Unavailable

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 9.28%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 90.56
Upside from Last Price: 86.44%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    47.6M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.2K KROS shares are owned by insiders